[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356659-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356659-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dsg2-cancer-stem-cells-co-located-with-fap-myofibroblasts-in-the-tumor-boundary-that-determines-the-efficacy-of-immunotherapy-in-non-small-cell-lung-cancer","DSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer","","Lung cancer remains a leading cause of cancer-related mortality owing to aggressiveness and heterogeneity. Cancer stem cells (CSCs) contribute to progression and therapeutic resistance, yet their transcriptional programs and spatial organization in non-small cell lung cancer (NSCLC) are not fully defined. Single-cell RNA sequencing and spatial transcriptomics integrate to map a 127-gene CSC signature with DSG2 as a dominant marker, enriched at tumor margins where DSG2+CSCs co-localize with FAP+ myofibroblasts (myCAFs).",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dsg2-cancer-stem-cells-co-located-with-fap-myofibroblasts-in-the-tumor-boundary-that-determines-the-efficacy-of-immunotherapy-in-non-small-cell-lung-cancer/356659/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dsg2-cancer-stem-cells-co-located-with-fap-myofibroblasts-in-the-tumor-boundary-that-determines-the-efficacy-of-immunotherapy-in-non-small-cell-lung-cancer/356659.png","ImageObject",300,407,{"name":42,"@type":43},"Jordan Avery","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main aim of the study in NSCLC?","Question",{"text":63,"@type":64},"To define CSC-associated phenotypes and their spatial organization in non-small cell lung cancer, and to determine how this relates to immunotherapy efficacy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the DSG2+ CSC program identified?",{"text":68,"@type":64},"Single-cell RNA sequencing and spatial transcriptomics were integrated, and weighted gene co-expression network analysis identified a 127-gene CSC signature with DSG2 as a dominant marker.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the relationship between DSG2+ CSCs and FAP+ myofibroblasts?",{"text":72,"@type":64},"Spatial mapping showed DSG2+CSCs preferentially enriched at tumor margins where they co-localize with FAP+ myofibroblasts (myCAFs), forming a niche linked to therapeutic resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356659,1790355908,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Advanced Science    \n[www.advancedscience.com](www.advancedscience.com)  \n RESEARCH ARTICLE   \nDSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblastsin the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer  \nGuangyu Fan1  Le Tang1  Tongji Xie1  Mengwei Yang1  Lin Li2  Sheng Yang1  Puyuan Xing1  Xiaohong Han3  Yuankai Shi1   \n1 Department of Medical Oncology, Beijing Key Laboratory of Key Technologies For Early Clinical Trial Evaluation of Innovative Drugs For Major Diseases, National Cancer Center /National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China  2 Department of Pathology, National Cancer Center / National Clinical Research Center For Cancer / Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China  3 Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory For Clinical Research and Evaluation of Drug, Peking Union Medical College Hospital, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China  \nCorrespondence: Puyuan Xing ([xingpuyuan@cicams.ac.cn](xingpuyuan@cicams.ac.cn))  Xiaohong Han (hanxiaohong@pumch.cn)  Yuankai Shi (syuankai@cicams.ac.cn)  \nReceived: 31 July 2025  Revised: 2 February 2026  Accepted: 5 February 2026  \nKeywords: cancer stem cells | EGFR-TKI therapy | immunotherapy | lung cancer | single-cell RNA sequencing | spatial transcriptomics  \nABSTRACT  \nLung cancer remains a leading cause of cancer-related mortality owing to its aggressiveness and pronounced heterogeneity. Cancer stem cells (CSCs) have been implicated in tumor progression and therapeutic resistance; however, their transcriptional programs and spatial organization in non-small cell lung cancer (NSCLC) are not fully characterized. Here, we integrated singlecell RNA sequencing with spatial transcriptomics to systematically define CSC-associated phenotype in NSCLC. Weighted gene co-expression network analysis identified a 127-gene CSC signature enriched for stemness-related pathways, with DSG2 emerging as a dominant marker. Elevated DSG2 expression was associated with chemotherapy resistance and predicted response to EGFR tyrosine kinase inhibitors based on independent clinical proteomic datasets. Spatial mapping revealed preferential enrichment of DSG2+CSCs at tumor margins, where they co-localized with FAP+myofibroblasts (myCAFs) . Multiplex immunofluorescence demonstrated that FAP+myCAFs expressed MMP9 and MMP12, consistent with a microenvironment supportive of epithelialmesenchymal transition and CSC maintenance. Functional co-culture assays showed that myCAFs enhanced CSC-associated phenotypes in DSG2ˆhigh tumor cells in an MMP-dependent manner. Collectively, these findings delineate a spatially organized DSG2+CSC–myCAF niche that contributes to therapeutic resistance in NSCLC.  \n1  Introduction  \nLung cancer remains one of the most lethal malignancies worldwide, characterized by pronounced biological heterogeneity,  \nrapid progression, and poor long-term outcomes [1, 2] . Nonsmall cell lung cancer (NSCLC) constitutes the majority of cases [3], yet survival remains unsatisfactory despite advancesin targeted therapy, immunotherapy, and early detection strate-  \n\n| Guangyu Fan, Le Tang, and Tongji Xie contributed equally to this work.\u003Cbr>|\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2026 The Author(s). Advanced Science published by Wiley-VCH GmbH |\n\nAdvanced Science, 2026; 13:e14543  \n[https://doi.org/10.1002/advs.202514543](https://doi.org/10.1002/advs.202514543)  \n1 of 18  \ngies. Across","cbCaigxUlDj6uIrr","https://ap.wps.com/l/cbCaigxUlDj6uIrr","pdf",12402168,18,"English","# Introduction\n## Background: NSCLC mortality and therapeutic resistance\n## CSCs, plasticity, and limitations of surface markers\n## CSC-driven remodeling of the tumor microenvironment","[{\"question\":\"What is the main aim of the study in NSCLC?\",\"answer\":\"To define CSC-associated phenotypes and their spatial organization in non-small cell lung cancer, and to determine how this relates to immunotherapy efficacy.\"},{\"question\":\"How was the DSG2+ CSC program identified?\",\"answer\":\"Single-cell RNA sequencing and spatial transcriptomics were integrated, and weighted gene co-expression network analysis identified a 127-gene CSC signature with DSG2 as a dominant marker.\"},{\"question\":\"What is the relationship between DSG2+ CSCs and FAP+ myofibroblasts?\",\"answer\":\"Spatial mapping showed DSG2+CSCs preferentially enriched at tumor margins where they co-localize with FAP+ myofibroblasts (myCAFs), forming a niche linked to therapeutic resistance.\"}]","DSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer | PDF",1790126672,45,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1cb8f92b0bd137456987ceb275e3db1d.webp",983,1283,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b5bafe37d80aa4465e8b25446c29a0a.webp",982,1281,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f775c303dcef401b81932a700531b3a.webp",981,1280,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3cccae809c4fe3d4cd701168fde37c9b.webp",980,1279]